Influenza viruses continually evolve through antigenic drift and shift, spreading via respiratory droplets and aerosols. Developing a universal nasal vaccine is essential for preventing seasonal and pandemic infections by inducing long-lasting immunity in the respiratory tract. The neonatal Fc receptor (FcRn) transfers IgG Abs across the epithelial barrier. This study investigates whether the i.n. delivery of the conserved Stalk antigen of HA, utilizing the FcRn, can stimulate protective immune responses against various influenza virus subtypes. We engineered a monomeric IgG Fc fused to a modified HA Stalk in its prefusion form. Mice i.n. immunized with Stalk-Fc exhibited significant protection against infections from H1N1, H5N1, H6N2, and H9N2 compared with groups of control mice. The immunized mice produced long-lasting HA Stalk–specific IgA and IgG Abs in nasal washes, bronchoalveolar lavage, and blood, along with tissue-resident memory T cells in the lungs and long-lived plasma cells in the bone marrow. This led to notably lower viral replication in the nasal turbinate and lungs. The Stalk-specific Abs demonstrated strong cross-reactivity against different influenza subtypes through neutralization, Ab- or complement-dependent cellular cytotoxicity, or phagocytosis. These results indicate that FcRn efficiently transports HA Stalk-Fc across the respiratory epithelial barrier, supporting the development of a universal influenza nasal vaccine.
Weizhong Li, Arunraj M. Rajendrakumar, ZiZhen Miao, Bibek Dhakal, Bogdan M. Domrachev, Tao Wang, Qiuqi Kan, Qiaofeng Wan, Hongquan Wan, Wenbin Tuo, Florian Krammer, Zhiping Ye, Xiaoping Zhu
The Editorial Board will only consider comments that are deemed relevant and of interest to readers. The Journal will not post data that have not been subjected to peer review; or a comment that is essentially a reiteration of another comment.